Страна: Велика Британія
мова: англійська
Джерело: MHRA (Medicines & Healthcare Products Regulatory Agency)
Benserazide hydrochloride; Levodopa
Lexon (UK) Ltd
N04BA02
Benserazide hydrochloride; Levodopa
25mg ; 100mg
Modified-release capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04090100
MADOPAR ® CR 125 CAPSULES (levodopa/benserazide) PATIENT INFORMATION LEAFLET PLEASE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. Your medicine is available using the above name but will be referred to as Madopar CR throughout this leaflet. WHAT IS IN THIS LEAFLET: 1. What Madopar CR is and what it is used for 2. What you need to know before you take Madopar CR 3. How to take Madopar CR 4. Possible side effects 5. How to store Madopar CR 6. Contents of the pack and other information 1. WHAT MADOPAR CR IS AND WHAT IT IS USED FOR Madopar CR capsules contain two medicines called levodopa and benserazide. They are used to treat Parkinson’s disease. People with Parkinson’s disease do not have enough dopamine in certain parts of their brains. This can result in slow movements, stiff muscles and tremor. Madopar CR works like this: - In your body the LEVODOPA is changed into dopamine. Dopamine is the active medicine that is needed in your brain to help Parkinson’s disease. - The BENSERAZIDE allows more of the levodopa you take to get into your brain, before it is changed into dopamine. The capsules are designed to release the medicines into your body slowly. This is why they are called ‘CR’ which stands for ‘controlled release’. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MADOPAR CR DO NOT TAKE MADOPAR CR IF: - You are allergic (hypersensitive) to levodopa, benserazide or any of the other ingredients of Madopar CR (listed in Section 6: Contents of the pack and other information). - You have a problem with the pressure in your eyes call Прочитайте повний документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Madopar CR 100 mg/25 mg Prolonged Release Hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 100.0mg Levodopa and 25mg Benserazide (as benserazide hydrochloride) For excipients see section 6.1 3 PHARMACEUTICAL FORM Prolonged-release capsules, hard Light blue opaque body and dark green opaque cap imprinted with ROCHE in red. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of all stages of Parkinson’s disease. Patients with fluctuations related to levodopa plasma concentrations or timing of dose, e.g. end of dose deterioration or wearing-off effects, are more likely to benefit from switching to Madopar CR. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS, INCLUDING THE ELDERLY Dosage and frequency of administration are very variable and must be titrated to the needs of the individual patient. Madopar CR capsules must always be swallowed whole, preferably with a little water. They may be taken 30 min before or one hour after meals but antacid preparations should be avoided. In patients with nocturnal immobility, positive effects have been reported after gradually increasing the last evening dose to two Madopar CR 100 mg/25 mg capsules on retiring. _PATIENTS NOT CURRENTLY TREATED WITH LEVODOPA _ In patients with mild to moderate disease, the initial recommended dose is one capsule of Madopar CR three times daily with meals. Higher doses, in general, of Madopar CR will be required than with conventional levodopa-decarboxylase inhibitor combinations as a result of the reduced bioavailability. The initial dosages should not exceed 600 mg per day of levodopa. Some patients may require a supplementary dose of conventional Madopar, or Madopar Dispersible, together with the first morning dose of Madopar CR to compensate for the more gradual onset of the CR formulation. In cases of poor response to Madopar CR at total daily doses of Madopar CR plus any supplementary conventional Madopar corresponding to 1200 mg levod Прочитайте повний документ